Research and Markets has announced the addition of the "Oral Mucositis - Pipeline Review, H2 2016" report to their offering.
'Oral Mucositis - Pipeline Review, H2 2016'; Oral Mucositis pipeline therapeutics constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by Companies and remaining by the Universities
Oral Mucositis Oral mucositis is the most common type of mucositis. It is a debilitating complication of cancer surgery, chemotherapy and radiation. Symptoms include change in color, hyposalivation, a change in the integrity of the mucosa and the presence of edema on the lips and/or the tongue. Treatment included oral decontamination (mouth care) and oral debridement.
'Oral Mucositis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Oral Mucositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews of key players involved in therapeutic development for Oral Mucositis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 7, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/kgt62z/oral_mucositis
Related Topics: Gastrointestinal Drugs
View source version on businesswire.com: http://www.businesswire.com/news/home/20160920005834/en/Business Wire
Last updated on: 20/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.